Clinical trials: Stereotactic Body Radiation Therapy
Locally Advanced Cervical Cancer
Stereotactic Body Radiation Therapy (SABR) for Definitive Treatment of Locally Advanced Cervical Cancer
The purpose of this study is to determine whether SABR boost therapy is effective in women with locally advanced cervical cancer without increased risk of acute gastrointestinal (GI) or genitourinary (GU) toxicity.
- Trial name
- NCT02045433
- Testing
- SABR Boost Therapy
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Texas Southwestern Medical Center
Carcinoma; Hepatocellular
Stereotactic Body Radiation Therapy for the Safety and Prognosis of Small Intrahepatic Recurrent HCC
Primary liver cancer is one of the common malignant tumors in China, of which hepatocellular carcinoma (HCC) accounts for 85%-90%.
- Trial name
- NCT05596630
- Testing
- Stereotactic body radiation therapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Pleural Mesothelial Neoplasm
Stereotactic Body Radiation Therapy With Immunotherapy for the Treatment of Mesothelioma
This phase I trial studies the effect of stereotactic body radiation therapy and immunotherapy in treating patients with mesothelioma.
- Trial name
- NCT04926948
- Testing
- Immunotherapy, Quality-of-Life Assessment, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
NSCLC (Advanced Non-small Cell Lung Cancer), EGFR Mutation Positive Advanced Non Small Cell Lung Cancer
ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs
The goal of this prospective study is to explore the safety and preliminary efficacy of stereotactic body radiotherapy (SBRT) combined with ORIENT-31 regimen (Sintilimab plus bevacizumab plus platinum-doublet chemotherapy) for…
- Trial name
- NCT06775743
- Testing
- ORIENT-31 regimen, SBRT
- Where
- China
- Volunteers
- 53 people
- Sponsor
- Fudan University
Non-small Cell Lung Cancer
Randomized Study to Compare CyberKnife to Surgical Resection In Stage I Non-small Cell Lung Cancer
Lung cancer remains the most frequent cause of cancer death in both men and women in the world. Surgical resection using lobectomy with mediastinal lymph node dissection or sampling has been a standard of care for operable early…
- Trial name
- STARS (NCT00840749)
- Testing
- CyberKnife Stereotactic Radiotherapy, Surgery
- Where
- 19 sites in United States, China and 2 more
- Volunteers
- 36 people
- Sponsor
- Accuray Incorporated
Spinal Metastases, Solid Tumor Cancer
Preoperative Stereotactic Radiotherapy for Treatment of Spinal Metastases
The goal of this interventional clinical trial is to evaluate the efficacy and safety of preoperative hypofractionated Stereotactic Body Radiotherapy (SBRT) in the treatment of patients undergoing surgery for spinal metastases.
- Trial name
- PRESTRASM (NCT07135817)
- Testing
- Preoperative Stereotactic Body Radiotherapy (SBRT), Spinal Surgery for Decompression and/or Stabilization
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- University Medical Center Goettingen
T1N0M0 Non-small Cell Lung Cancer
A Phase II Study of Stereotactic Body Radiation Therapy in Patients With T1N0M0 Non-small Cell Lung Cancer (JCOG0403)
To evaluate the efficacy and safety of SBRT for T1N0M0 non-small cell lung cancer
- Trial name
- NCT00238875
- Testing
- stereotactic body radiation therapy
- Where
- 16 sites in Japan
- Volunteers
- 167 people
- Sponsor
- Haruhiko Fukuda
Brain Metastases
A Dose Escalation Trial of Five Fraction Stereotactic Radiation Therapy for Brain Metastases
This study looks at dose escalation for five fraction stereotactic radiotherapy for patients diagnosed with brain metastases with tumors 2.1-4.0 cm in diameter or 4.1-6.0 cm in diameter.
- Trial name
- RAD1705 (NCT03412812)
- Testing
- 6 Gy, 7 Gy, 8 Gy
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Alabama at Birmingham
Advanced Colorectal Cancer, Circulating Tumor DNA
Circulating Tumor DNA Guided Therapeutic Strategies for CRC Patients With Small Pulmonary Nodules
The clinical diagnosis and treatment of small pulmonary nodules (suspected to be lung metastases) in advanced colorectal cancer patients remain controversy.
- Trial name
- NCT05495672
- Testing
- Local treatment
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Junjie Peng
NSCLC
Stereotactic Body Radiotherapy for the Treatment of OPD
HALT is a phase II, randomised multi-centre study with integrated seamless continuation to phase III trial following acceptable safety and feasibility assessment.
- Trial name
- HALT (NCT03256981)
- Testing
- SBRT, TKI
- Where
- 29 sites in France, Italy and 3 more
- Volunteers
- 113 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer
This phase II trial studies the effect of standard of care chemotherapy with or with out stereotactic body radiation therapy in treating patients with pancreatic cancer that has spread to a limited amount of places in the body…
- Conditions
- Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8, Recurrent Pancreatic Adenocarcinoma, Oligometastatic Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT04975516
- Testing
- Chemotherapy, Stereotactic Body Radiation Therapy, Computed Tomography
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Mayo Clinic
Renal Cell Carcinoma
Trial Comparing Stereotactic Body Radiation Therapy to Radiofrequency Ablation for Renal Cell Carcinoma
This study will assess whether Stereotactic Body Radiation Therapy (SBRT) can provide comparable local control, with similar or improved toxicity rates compared to Radio Frequency Ablation (RFA) when treating small renal cell…
- Trial name
- NCT02138578
- Testing
- SBRT, RFA
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Michigan Rogel Cancer Center
Prostate Cancer
Standard Moderately Hypofractionated RT vs. Ultra-hypofractionated Focal Lesion Ablative Microboost in Prostate Cancer
EBRT is one of the standard treatment options for patients with localized PCA. Based on the outcome of randomized trials, moderately hypofractionated RT(19-25 fractions of 2.5-3.4Gy) is considered equivalent to conventional…
- Trial name
- NCT05705921
- Testing
- Radiotherapy standard, Radiotherapy Hypo-FLAME
- Where
- Netherlands
- Volunteers
- 484 people
- Sponsor
- The Netherlands Cancer Institute
Oligometastases of the Spine
Pilot Study of Same-session MR-only Simulation and Treatment With Stereotactic MRI-guided Adaptive Radiotherapy (SMART) for Oligometastases of the Spine
In light of the increasing experience with magnetic resonance image-guided radiotherapy (MRgRT) and adaptive planning and advances in magnetic resonance (MR)-only planning, the investigators propose here to evaluate the…
- Trial name
- NCT03878485
- Testing
- MRIdian Linac System from ViewRay, Stereotactic MRI-guided Adaptive Radiotherapy
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
Non Small Cell Lung Cancer
Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC
This is a randomized Phase II study which is designed to determine the impact of stereotactic radiotherapy and durvalumab on quality-of-life and oncologic outcomes in patients with advanced non-small cell lung cancer.
- Trial name
- NCT04786093
- Testing
- Stereotactic radiation therapy, Durvalumab
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Texas Southwestern Medical Center
Lung Cancer, Oligometastatic Lung Tumor
One Fraction Simulation-Free Treatment With CT-Guided Stereotactic Adaptive Radiotherapy for Patients With Oligometastatic and Primary Lung Tumors
Stereotactic body radiotherapy (SBRT) has become a standard of care for medically inoperable or high-risk operable early-stage non-small cell lung cancer (NSCLC) patients.
- Trial name
- ONE STOP (NCT06236516)
- Testing
- One fraction stereotactic body radiotherapy, HyperSight, Ethos
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Washington University School of Medicine
Endometrial Cancer
POSE - POs Surgery Endometrial Cancer
This phase I/II feasibility study of hypo-fractionated, image-guided Volumetric Modulated Arc Therapy (VMAT) Stereotactic Body Radiotherapy (SBRT) to the vaginal cuff in intermedium and high risk endometrial cancer.
- Trial name
- POSE (NCT06394258)
- Testing
- Stereotactic body radiotherapy (SBRT)
- Where
- Portugal
- Volunteers
- 30 people
- Sponsor
- Fundacao Champalimaud
Brain Metastases, Adult, Breast Cancer
BEAT-Breast: Trial of DE-iPTV in Patients With Primary Breast Cancer With Brain Metastases Who Are Not Suitable for Stereotactic Radiotherapy.
The aim of this study is to demonstrate if it is possible to delivering a novel and modern radiotherapy approach (Dose Escalated internal PTV (DE-iPTV)) and to collect health related quality of life in patients whose breast…
- Trial name
- BEAT-Breast (NCT06611306)
- Testing
- DE-iPTV
- Where
- 2 sites in United Kingdom
- Volunteers
- 42 people
- Sponsor
- Imperial College London
Advanced Oligometastatic Non-small Cell Lung Cancer
A Study of TQB2450 Injection Combined With Stereotactic Body Radiation Therapy (SBRT) in Subjects With Advanced Oligometastatic Non-Small Cell Lung Cancer
TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and…
- Trial name
- NCT04306926
- Testing
- TQB2450, SBRT
- Where
- 4 sites in China
- Volunteers
- 59 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non Small Cell Lung Cancer
Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal Metastases
A Single-Arm Clinical Study of Furmonertinib (160mg) Combined with Intrathecal Chemotherapy (ITC) and Stereotactic Radiotherapy (SRT) as First-Line Treatment in EGFR Classic Mutation-Positive NSCLC Patients with Brain Parenchymal…
- Trial name
- NCT07304739
- Testing
- Furmonertinib, Intrathecal chemotherapy, Stereotactic radiotherapy
- Where
- 3 sites in China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.